查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566968

乳癌筛检市场：按测试类型、性别和最终用户：2024-2033 年全球机会分析和产业预测

Breast Cancer Screening Market By Test Type , By Gender By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年乳癌筛检市值为29亿美元，预计2024年至2033年复合年增长率为8.7%，到2033年达到67亿美元。

乳癌筛检是一项重要的公共卫生策略，旨在早期发现乳癌，这是全世界女性中最常见的癌症。这种预防措施的主要目标是在可以治疗的早期阶段发现癌症。乳房X光摄影是最广泛使用的筛检工具，经常使用已被证明可以降低乳癌死亡率。透过及早发现肿瘤，乳癌筛检有助于增加成功治疗的机会、提高存活率并减少以后更积极治疗的需要。

全球乳癌筛检市场的成长是由全球乳癌盛行率的惊人成长、人们对早期检测方法的认识和需求的提高所推动的。根据世界卫生组织（WHO）2024年3月发布的研究，2022年全球将有约230万名女性被诊断出罹患乳癌，通报死亡人数将达67万人。此外，政府和医疗保健组织越来越多地透过宣传宣传活动、津贴和有组织的筛检计划来促进乳癌筛检，以方便获得筛检服务。根据美国疾病管制与预防中心美国发布的一项研究，大约 76.4% 的 50 至 74 岁女性在过去两年内接受过乳房 X 光检查。这项统计数据反映了美国各地公共卫生宣传活动的有效性和筛检服务的可近性。此外，老年女性人口的迅速增加对市场成长做出了重大贡献。这是因为，老年女性由于免疫力下降、基因突变累积和乳房组织变化，罹患乳癌的风险更高。越来越重视年轻女性的早期筛检和开发非侵入性筛检方法是进一步推动市场成长的关键趋势。然而，乳癌筛检的高成本，尤其是 3D乳房X光摄影和 MRI 等先进技术，是全球市场的主要阻碍因素。此外，由于缺乏医疗基础设施、训练有素的专业人员和行动筛检单位，农村和服务欠缺地区的医疗服务有限，也严重限制了马苏的市场成长。相反，数位乳房乳房X光摄影、3D乳房X光摄影和MRI等影像技术的创新正在提高乳癌筛检的准确性和效率。这些进步使筛检变得更加容易和可靠，并有望为全球市场扩张提供机会。为了改善偏远和服务欠缺地区获得乳癌筛检的机会，正在引入移动乳房X光摄影机，以解决获得医疗保健机会有限的问题。预计此类倡议将在不久的将来为市场成长开闢新的途径。

全球乳癌筛检产业按测试类型、性别、最终用户和地区进行细分。依检测类型分为血液标记检测、基因检测、影像检查、免疫组织化学检测等。从性别上来说，他们分为男性和女性。依最终用户划分，可分为专科诊所、医院、诊断中心等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按检测类型划分，2023 年影像检查领域占市场占有率。

从性别来看，2023 年女性市场占有率最大。

从最终用户来看，医院将成为2023年占据份额的主要细分市场。

按地区划分，北美将在 2023 年占据主导地位，而亚太地区预计在预测期内复合年增长率最高。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章乳癌筛检市场：依测试类型

  • 市场概况
  • 血液标记测试
  • 基因检测
  • 影像检查
  • 免疫组织化学

第五章乳癌筛检市场：性别

  • 市场概况
  • 男性
  • 女士

第六章乳癌筛检市场：依最终用户分类

  • 市场概况
  • 专科诊所
  • 医院
  • 诊断中心
  • 其他的

第七章乳癌筛检市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国乳癌筛检市场
    • 加拿大乳癌筛检市场
    • 墨西哥乳癌筛检市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国乳癌筛检市场
    • 法国乳癌筛检市场
    • 英国乳癌筛检市场
    • 义大利乳癌筛检市场
    • 西班牙乳癌筛检市场
    • 其他欧洲乳癌筛检市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本乳癌筛检市场
    • 中国乳癌筛检市场
    • 澳洲乳癌筛检市场
    • 印度乳癌筛检市场
    • 韩国乳癌筛检市场
    • 其他亚太乳癌筛检市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西乳癌筛检市场
    • 沙乌地阿拉伯乳癌筛检市场
    • 南非乳癌筛检市场
    • 其他拉丁美洲/中东/非洲乳癌筛检市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Siemens Healthineers AG
  • Myriad Genetics, Inc.
  • Metabolomic Technologies Inc
  • Biocrates Lifesciences AG
  • A&G Pharmaceutical
  • Provista Diagnostics Inc
  • F. Hoffmann-La Roche AG
  • Volpara Health Limited
  • Quest Diagnostics Inc.
  • GE Healthcare
简介目录
Product Code: A324383

The breast cancer screening market was valued at $2.9 billion in 2023, and is projected to reach $6.7 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Breast cancer screening is a critical public health strategy aimed at early detection of breast cancer, the most common cancer among women globally. The primary goal of this preventative measure is to identify cancer at an early stage when it is most treatable. Mammography is the most widely used screening tool, and its regular use has been shown to reduce mortality rates from breast cancer. By detecting tumors early, breast cancer screening increases the chances of successful treatment, improves survival rates, and can help to reduce the need for more aggressive treatments later on.

The growth of the global breast cancer screening market is driven by alarming increase in the global prevalence of breast cancer and rise in awareness and demand for early detection methods. According to a study published in March 2024 by the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer and 670,000 deaths were reported globally in 2022. Furthermore, governments and healthcare organizations are increasingly promoting breast cancer screening through awareness campaigns, subsidies, and organized screening programs, which have encouraged easy access to screening services. According to a study published by the U.S. Centers for Disease Control and Prevention in 2022, approximately 76.4% of women aged 50-74 underwent a mammogram within the past two years. This statistic reflects the effectiveness of public health campaigns and the accessibility of screening services across the U.S. Moreover, surge in aged women population significantly contributes toward the market growth. This is attributed to the fact that aged women are at higher risk of developing breast cancer due to weakened immune system, accumulation of genetic mutations, and changes in breast tissue. Rise in emphasis on early screening in younger women and development of non-invasive screening methods are the key trends are that further fostering the market growth. However, high cost associated with breast cancer screening, particularly advanced technologies like 3D mammography or MRI, acts as a key deterrent factor of the global market. In addition, limited access in rural and underserved areas due to lack of healthcare infrastructure, trained professionals, and mobile screening units significantly restrains the market growth. On the contrary, innovations in imaging technologies, such as digital mammography, 3D mammography, and MRI, are enhancing the accuracy and efficiency of breast cancer screening. These advancements are making screening more accessible and reliable, which are expected to offer remunerative opportunities for the expansion of the global market during the market. To improve access to breast cancer screening in remote and underserved areas, mobile mammography units are being introduced to address the concern of limited access to healthcare. Such initiatives are anticipated to open new avenues for the market growth in the near future.

The global breast cancer screening industry is segmented into test type, gender, end user, and region. By test type, the market is divided into blood marker test, genetic test, imaging test, and immunohistochemistry test. According to gender, it is divided into male and female. As per end user, it is fragmented into specialty clinics, hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By test type, the imaging test segment dominated the market share in 2023.

According to gender, the female segment exhibited the largest market share in 2023.

As per end user, hospital emerged as the leading segment, in terms of share, in 2023.

Region wise, North America holds a dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global breast cancer screening market include Siemens Healthineers AG, Myriad Genetics, Inc., Metabolomic Technologies Inc, Biocrates Lifesciences AG, A&G Pharmaceutical, Provista Diagnostics Inc, F. Hoffmann-La Roche AG, Volpara Health Limited, Quest Diagnostics Inc., and GE Healthcare. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Test Type

  • Blood Marker Test
  • Genetic Test
  • Imaging Test
  • Immunohistochemistry Test

By Gender

  • Male
  • Female

By End User

  • Specialty Clinics
  • Hospitals
  • Diagnostic Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Siemens Healthineers AG
    • Myriad Genetics, Inc.
    • Metabolomic Technologies Inc
    • Biocrates Lifesciences AG
    • A&G Pharmaceutical
    • Provista Diagnostics Inc
    • F. Hoffmann-La Roche AG
    • Volpara Health Limited
    • Quest Diagnostics Inc.
    • GE Healthcare

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BREAST CANCER SCREENING MARKET, BY TEST TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Test Type
  • 4.2. Blood Marker Test
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Genetic Test
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Imaging Test
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Immunohistochemistry Test
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: BREAST CANCER SCREENING MARKET, BY GENDER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Gender
  • 5.2. Male
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Female
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: BREAST CANCER SCREENING MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Specialty Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Hospitals
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centers
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Other
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: BREAST CANCER SCREENING MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Test Type
    • 7.2.3. Market Size and Forecast, By Gender
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Breast Cancer Screening Market
      • 7.2.6.1. Market Size and Forecast, By Test Type
      • 7.2.6.2. Market Size and Forecast, By Gender
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Breast Cancer Screening Market
      • 7.2.7.1. Market Size and Forecast, By Test Type
      • 7.2.7.2. Market Size and Forecast, By Gender
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Breast Cancer Screening Market
      • 7.2.8.1. Market Size and Forecast, By Test Type
      • 7.2.8.2. Market Size and Forecast, By Gender
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Test Type
    • 7.3.3. Market Size and Forecast, By Gender
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Breast Cancer Screening Market
      • 7.3.6.1. Market Size and Forecast, By Test Type
      • 7.3.6.2. Market Size and Forecast, By Gender
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Breast Cancer Screening Market
      • 7.3.7.1. Market Size and Forecast, By Test Type
      • 7.3.7.2. Market Size and Forecast, By Gender
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Breast Cancer Screening Market
      • 7.3.8.1. Market Size and Forecast, By Test Type
      • 7.3.8.2. Market Size and Forecast, By Gender
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Breast Cancer Screening Market
      • 7.3.9.1. Market Size and Forecast, By Test Type
      • 7.3.9.2. Market Size and Forecast, By Gender
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Breast Cancer Screening Market
      • 7.3.10.1. Market Size and Forecast, By Test Type
      • 7.3.10.2. Market Size and Forecast, By Gender
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Breast Cancer Screening Market
      • 7.3.11.1. Market Size and Forecast, By Test Type
      • 7.3.11.2. Market Size and Forecast, By Gender
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Test Type
    • 7.4.3. Market Size and Forecast, By Gender
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Breast Cancer Screening Market
      • 7.4.6.1. Market Size and Forecast, By Test Type
      • 7.4.6.2. Market Size and Forecast, By Gender
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Breast Cancer Screening Market
      • 7.4.7.1. Market Size and Forecast, By Test Type
      • 7.4.7.2. Market Size and Forecast, By Gender
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. Australia Breast Cancer Screening Market
      • 7.4.8.1. Market Size and Forecast, By Test Type
      • 7.4.8.2. Market Size and Forecast, By Gender
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. India Breast Cancer Screening Market
      • 7.4.9.1. Market Size and Forecast, By Test Type
      • 7.4.9.2. Market Size and Forecast, By Gender
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Breast Cancer Screening Market
      • 7.4.10.1. Market Size and Forecast, By Test Type
      • 7.4.10.2. Market Size and Forecast, By Gender
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Breast Cancer Screening Market
      • 7.4.11.1. Market Size and Forecast, By Test Type
      • 7.4.11.2. Market Size and Forecast, By Gender
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Test Type
    • 7.5.3. Market Size and Forecast, By Gender
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Breast Cancer Screening Market
      • 7.5.6.1. Market Size and Forecast, By Test Type
      • 7.5.6.2. Market Size and Forecast, By Gender
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Breast Cancer Screening Market
      • 7.5.7.1. Market Size and Forecast, By Test Type
      • 7.5.7.2. Market Size and Forecast, By Gender
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Breast Cancer Screening Market
      • 7.5.8.1. Market Size and Forecast, By Test Type
      • 7.5.8.2. Market Size and Forecast, By Gender
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Breast Cancer Screening Market
      • 7.5.9.1. Market Size and Forecast, By Test Type
      • 7.5.9.2. Market Size and Forecast, By Gender
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Siemens Healthineers AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Myriad Genetics, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Metabolomic Technologies Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Biocrates Lifesciences AG
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. A&G Pharmaceutical
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Provista Diagnostics Inc
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. F. Hoffmann-La Roche AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Volpara Health Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Quest Diagnostics Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GE Healthcare
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments